CAR-NK 细胞中 IL-10 的耗竭增强肿瘤微环境的重编程并改善治疗效果
Depletion of IL-10 in CAR-NK cells augments reprogramming of the tumor microenvironment and ameliorates therapeutic efficacy.
我们的研究结果表明,抑制IL-10分泌可增强CAR工程化NK-92细胞的治疗潜力,提示这一策略有望成为临床转化的有前景途径。
ALL SOURCES
Depletion of IL-10 in CAR-NK cells augments reprogramming of the tumor microenvironment and ameliorates therapeutic efficacy.
我们的研究结果表明,抑制IL-10分泌可增强CAR工程化NK-92细胞的治疗潜力,提示这一策略有望成为临床转化的有前景途径。
Metabolic and Post-Translational Vulnerabilities of Glioblastoma: Disulfidptosis, Glycosylation, and Implications for CAR-T Therapy.
胶质母细胞瘤(GB)仍是治疗抵抗性最强的实体瘤之一,其特征是显著的代谢可塑性、瘤内异质性和高度免疫抑制的微环境。
Chimeric Antigen Receptor-T Cell Therapy for Pediatric and Young Adult Primary Central Nervous System Tumors: A Systematic Review of Early Phase Clini
初步临床经验表明,针对儿童和年轻成人 CNS 肿瘤的 CAR-T 细胞疗法具有生物学活性且临床可行,其毒性特征独特但可控。
ErbB2/HER2-targeted CAR-NK cells eliminate breast cancer cells in an organoid model that recapitulates tumor progression.
嵌合抗原受体工程化 NK 细胞在过继性肿瘤免疫治疗中展现出前景。
CAR T cell therapy for glioblastoma: A review of the first decade of clinical trials.
胶质母细胞瘤(GBM)是一种侵袭性原发性脑肿瘤,预后不良,有效治疗方案很少。
Advances in CAR-T therapy for central nervous system tumors.
CAR-T 细胞疗法在中枢神经系统肿瘤中的应用已取得显著进展;
Natural killer cell dysfunction in glioma: from immune evasion to immunotherapy.
自然杀伤(NK)细胞是固有免疫的关键组成部分,无需预先致敏即具有清除肿瘤细胞的能力。
Chimeric antigen receptor T cell therapy for glioblastoma: overcoming current barriers and strategies to enhance efficacy for therapeutic implications
胶质母细胞瘤(GBM)是一种高度恶性的原发性脑肿瘤,其特点是治疗选择有限且生存结局差。
Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma.
颅内注射HER2靶向CAR-NK细胞在复发性GB患者中是可行且安全的。1 108个NK-92/5.28.z细胞被确定为后续扩展队列重复局部注射CAR-NK细胞的最大可行剂量。
Convection-enhanced delivery of nanoencapsulated gene locoregionally yielding ErbB2/Her2-specific CAR-macrophages for brainstem glioma immunotherapy.
巨噬细胞(M s)在实体肿瘤微环境(TME)中表现出独特的效应功能和高度的浸润性,尤其是在大脑中,M s 在那里发挥结构性支持作用,并且作为中枢神经系统的主要免疫效应细胞,占脑细胞的5-12%。
MEMBER ACCOUNT
登录成功会直接打开下一页。